Progressive Supranuclear Palsy Treatment Market Is Expanding Rapidly As Alzprotect Entered Into A Partnership With PAREXEL Biotech To Perform The Clinical Phase 2a Development Of AZP2006 For The Treatment Of PSP
Progressive Supranuclear Palsy is a condition of temporarily paralyzed muscles in the face, hands, and feet. It is usually caused by an accident or injury to one of the central nervous system nerves or the spinal cord. When this condition is left untreated, it can result in permanent disability. The cause of the disorder is unknown, although a variety of causes have been proposed including genetic anomalies, neurological problems, tumors, and brain defects. In most cases, however, the disorder is idiopathic.
Rising incidence of progressive supranuclear
palsy (PSP) is expected to drive growth of the global progressive supranuclear
palsy treatment market. PSP is one of the rarest and undiagnosed disorders and
hence it is difficult to know how many people are affected. According to the
National Organization for Rare Disorders (NORD), around 20,000 people in the
U.S. are affected by PSP with as many as 5-7 in 100,000. According to the same
source, the onset of this disorder occurs between 45 and 75 years of age, with
the average age of onset being 65 years. As a result of this demand for PSP,
treatment has increased significantly. Hence, these factors are expected to
drive growth of the global progressive supranuclear palsy treatment market.
Furthermore, continuous R&D activities and trials for treatment PSS are
expected to propel the global progressive supranuclear palsy treatment market
growth in the near future.
Lack of knowledge regarding diagnosis
PSP and inadequate research and development is expected to hinder the global
progressive supranuclear palsy treatment market growth in the near future.
Among regions, North America is expected to witness significant growth in the
global progressive supranuclear palsy treatment market. This is owing to the
presence of robust and state-of-the-art neural research facilities in the U.S.
and Canada. Furthermore, Europe is expected to register a robust growth rate,
owing to the presence of major market players such as Novartis AG,
GlaxoSmithKline, and more.
Key players involved in the global
progressive supranuclear palsy treatment market are Novartis AG,
GlaxoSmithKline, AbbVie Inc., TauRx Pharmaceuticals, Teva Pharmaceutical
Industries Ltd., Acorda Therapeutics Inc., Asceneuron Therapeutics, Biogen
Inc., AlzProtect, Bristol-Myers Squibb Co.,
UCB Biopharma, Merck & Co. Inc., and TauRx Pharmaceuticals.
For instance, in March 2019,
AlzProtect, a biopharmaceutical company, partnered with PAREXEL Biotech, a
subsidiary of PAREXEL International Corporation, to perform the clinical phase
2a development of AZP2006 for the treatment of PSP.
Comments
Post a Comment